Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
1999 1
2001 3
2002 9
2003 10
2004 6
2005 4
2006 1
2007 1
2008 3
2009 6
2010 3
2011 3
2012 2
2013 2
2014 4
2015 9
2016 2
2017 2
2018 1
2019 5
2020 6
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

74 results
Results by year
Filters applied: . Clear all
Page 1
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka M, Koenig LM, Formisano S, Boehmer DFR, Vick B, Heuer EM, Meinl H, Kocheise L, Zeitlhöfler M, Ahlfeld J, Kobold S, Endres S, Subklewe M, Duewell P, Schnurr M, Jeremias I, Lichtenegger FS, Rothenfusser S. Ruzicka M, et al. Among authors: rothenfusser s. Leukemia. 2020 Apr;34(4):1017-1026. doi: 10.1038/s41375-019-0639-x. Epub 2019 Nov 18. Leukemia. 2020. PMID: 31740809 Free PMC article.
Reply.
Hoffmann F, Endres S, Rothenfusser S. Hoffmann F, et al. Among authors: rothenfusser s. Hepatology. 2016 Mar;63(3):1062-3. doi: 10.1002/hep.27955. Epub 2015 Jul 23. Hepatology. 2016. PMID: 26106015 No abstract available.
Immunotherapy in Tumors.
Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S. Kobold S, et al. Among authors: rothenfusser s. Dtsch Arztebl Int. 2015 Nov 27;112(48):809-15. doi: 10.3238/arztebl.2015.0809. Dtsch Arztebl Int. 2015. PMID: 26667979 Free PMC article. Review.
Strategies to relieve immunosuppression in pancreatic cancer.
Schnurr M, Duewell P, Bauer C, Rothenfusser S, Lauber K, Endres S, Kobold S. Schnurr M, et al. Among authors: rothenfusser s. Immunotherapy. 2015;7(4):363-76. doi: 10.2217/imt.15.9. Immunotherapy. 2015. PMID: 25917628 Review.
Modes of action of TLR7 agonists in cancer therapy.
Kobold S, Wiedemann G, Rothenfußer S, Endres S. Kobold S, et al. Among authors: rothenfusser s. Immunotherapy. 2014;6(10):1085-95. doi: 10.2217/imt.14.75. Immunotherapy. 2014. PMID: 25428647 Review.
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma.
Meßner M, Schmitt S, Ardelt MA, Fröhlich T, Müller M, Pein H, Huber-Cantonati P, Ortler C, Koenig LM, Zobel L, Koeberle A, Arnold GJ, Rothenfußer S, Kiemer AK, Gerbes AL, Zischka H, Vollmar AM, Pachmayr J. Meßner M, et al. Among authors: rothenfusser s. FASEB J. 2020 Sep;34(9):11860-11882. doi: 10.1096/fj.202001128R. Epub 2020 Jul 11. FASEB J. 2020. PMID: 32652772
A Novel Complete Autosomal-Recessive STAT1 LOF Variant Causes Immunodeficiency with Hemophagocytic Lymphohistiocytosis-Like Hyperinflammation.
Boehmer DFR, Koehler LM, Magg T, Metzger P, Rohlfs M, Ahlfeld J, Rack-Hoch A, Reiter K, Albert MH, Endres S, Rothenfusser S, Klein C, Koenig LM, Hauck F. Boehmer DFR, et al. Among authors: rothenfusser s. J Allergy Clin Immunol Pract. 2020 Oct;8(9):3102-3111. doi: 10.1016/j.jaip.2020.06.034. Epub 2020 Jun 27. J Allergy Clin Immunol Pract. 2020. PMID: 32603902
74 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page